期刊文献+

抗厌氧菌类抗生素耐药机制及其临床使用的研究进展 被引量:8

Research Progress on Resistant Mechanism of Anti-anaerobic Antibiotics and its Clinical Medication
下载PDF
导出
摘要 厌氧菌是人体内正常菌群的主要组成部分,但同时也可引起人体多类内源性疾病的致病菌群。由于现代培养及分离条件的提高,针对厌氧致病菌的研究日益增多,而抗生素疗法作为主要的厌氧菌疾病治疗方法也进一步引起科学家和医药工作者的关注。与此同时,厌氧菌的耐药性逐渐增强,因此新抗生素的发现成为治疗厌氧菌感染的新目标。综述常用致病厌氧菌的耐药机制以及各类抗厌氧菌药物的使用文献资料,并对其研究进展做了分析。 Anaerobic bacteria are important constituents of the body normal flora,but can cause many kinds of endogenous disease pathogenic bacteria in human body. Because of improving modern culture and separation conditions,study on anaerobic pathogenic bacteria is increasing day by day. Antibiotic therapy as primary treatment of anaerobic bacteria disease, attracts a further attention from scientists and medical workers. At the same time, the resistance increases gradually, and the discovery of novel antibiotics becomes a new target for treating anaerobic bacteria infection.The of the literature of common pathogenic anaerobic bacteria, resistance mechanism and the clinical medication of all kinds of anti-anaerobic agents were reviewed, and the research progress was analyzed.
出处 《抗感染药学》 2015年第4期481-486,共6页 Anti-infection Pharmacy
关键词 厌氧菌 抗生素 耐药机制 临床用药 anaerobe antibiotics mechanisms of resistance clinical medication
  • 相关文献

参考文献20

  • 1Bartlett JG. How important are anaerobic bacteria in aspi- ration pneumonia: when should they be treated and what is optimal therapy[J]. Infect Dis Clin NortAmer, 2013, 27 (1): 149-155.
  • 2Hecht DW. Anaerobes: antibiotic resistance, clinical sig- nificance, and the role of susceptibility testing [EB/OL]. http://link.springer.com/article/10.1007% 2Fs15010- 012- 0389-4, 2013-02-01.
  • 3Hostler C J, Chen LF. Fidaxomicin for treatment of clostrid- ium difficile-associated diarrhea and its potential role for prophylaxis[J]. Exp Opin Pharmacoth, 2013, 14(11): 1529-1536.
  • 4邓万俊.抗生素治疗厌氧菌性心包炎的研究进展[J].国外医药(抗生素分册),2010,31(2):58-62. 被引量:3
  • 5顾觉奋,黄文睿,刘亚光.厌氧菌及抗厌氧菌抗菌药的研究进展[J].抗感染药学,2008,5(3):129-133. 被引量:9
  • 6Brook I. Antimicrobial treatment of anaerobic infections[J]. Exp Opin Pharmacoth, 2011, 12(11 ): 1691 - 1707.
  • 7Dubreuil LJ, Mahieux S, Neut C, et al. Anti-anaerobic ac- tivity of a new [3-1actamase inhibitor NXL104 in combina- tion with 13-lactams and metronidazole[J], lnt J Antimicr Ag, 2012, 39(6): 500-504.
  • 8Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone[J]. Int J Antimierob Agents, 2012, 39(6):534-538.
  • 9Betriu C, Culebras E, G6mez M, et al.Comparative in vi- tro activity of ceftobiprole against Gram-positive cocci [J]. lnt JAntimicrob Agents, 2010, 36(2): 111-113.
  • 10Kreskena M, K6ber-Irrganga B, L~ifferb J, et al. In vitro activities of ceftobiprole combined with amikacin or levo- floxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology[J], lnt J An- timicrob Agents, 2011, 38(1):70-75.

二级参考文献53

  • 1周澎涛,刘蕾.新型静脉用甘氨酰环素类抗菌药替加环素[J].中国新药杂志,2007,16(4):328-332. 被引量:13
  • 2[1]Ednie L,Shapiro S,Appelbaum PU.Antianaerobe activity of ceflobiprole,a new broad-spectrum cephalosporin[J].Diagn Microbiol Infec Dis,2007,58(1):133-136.
  • 3[2]Merriam CV,Citron DM,Tyrrell KL,et al.In vitro activity of azithromycin and nine comparator agents against 296 strains of oral anaerobes and 31 strains of Eikenella corrodens[J].Int J Antimicrob Agents,2006,28(3):244-248.
  • 4[3]Stein GE,Schooley S,Tyrreil KL,et al.Human serum activity of telithromycin,azithromycin and amoxicillin/clavulanate against aerobic and anaerobic respiratory pathogens[J].Int J Antimicrob Agents.2007,29(1):39-43.
  • 5[4]Snydman DR,Jacobus NV,McDermott LA,et al.National Survey on the Susceptibility of Bacteroides fragilis Group:Report and Analysis of Trends in the United States from 1997 to 2004[J].Antimicrob Agents Chemother.2007,51 (5):1649-1655.
  • 6[5]Koeth LM,Good CE,Appelbaum PC,et el.Surveillance of sus ceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents[J].J Antimicrob Chemother,2004,53(6):1039-1044.
  • 7[6]Aldridge KE,Ashcraft D,Cambre K,et el.Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group,Prevotella.Fusobacterium,Porphyromonas,and Peptostreptococcus species[J].Antimicrob Agents Chemother,2001,45(4):1238-1243.
  • 8[7]Pankuch GA,Appelbaum PC.Activities of Tizoxanide and Nitazoxanide compared to those of five other Thiazolides and three other agent against Anaerobic Species[J].Antimicrob Agents Chemother,2006,50(3):1112-1117.
  • 9[8]Finegold SM,Song Y,Liu C,at al.Clostridium clostridioforme:a mixture o f three clinically important species[J].Eur J Clin Microbiol Infect Dis,2005,24(5):319-324.
  • 10[9]Tanaka K,Mikamo H,Nakao K,et al.In vitro anacrobic activity of DX-619,a new Des-fluoro(6) quinolone[J].Antimicrob Agents Chemother,2 006,50(11):3908-3913.

共引文献12

同被引文献67

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部